Explore the latest insights on Ruxolitinib in Steroid Refractory Chronic GvHD, as two experts share their perspectives on advancements and considerations in the field.
EP. 1: Clinical Evolution of Treatment in Chronic Graft vs. Host Disease
Dr. Zeiser discusses the dynamic clinical evolution of Graft vs Host Disease (GvHD) in a concise overview, gaining insights into its progression and changing manifestations over time.
EP. 2: Navigating GvHD: Overview and Differences between Acute and Chronic GvHD
Two experts explore the essentials of Graft vs Host Disease (GvHD), understanding its symptoms, diagnosis, and distinguishing characteristics between acute and chronic forms.
EP. 3: First line Treatment and Challenges in Chronic GvHD
Explore the primary treatment options for chronic Graft vs Host Disease (cGvHD) and delve into the challenges associated with prolonged steroid use, focusing on dosing strategies and adverse event management.
EP. 4: REACH3: Ruxolitinib in Steroid Refractory cGvHD
Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.
EP. 5: Use of Subsequent Therapies in SR/D cGvHD
Experts discuss the treatments for steroid-refractory/dependent chronic Graft vs Host Disease (SR/D cGvHD), focusing on the unique mechanisms and applications of belumosudil and role of ibrutinib.
EP. 6: Future Therapies in cGvHD
Dr. Zeiser and Dr. Chao review ongoing clinical trials in the management of cGvHD – specifically the use of axatilimab and abatacept in SR/D cGvHD.
EP. 7: Navigating Unmet Needs in SR/D cGvHD
Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
2 Commerce Drive Cranbury, NJ 08512